

# Vladimir Strugov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7688320/publications.pdf>

Version: 2024-02-01

8  
papers

468  
citations

2258059

3  
h-index

2053705

5  
g-index

8  
all docs

8  
docs citations

8  
times ranked

680  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 43-56.	10.7	448
2	Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2018, 97, 2153-2161.	1.8	10
3	Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE. <i>Blood</i> , 2018, 132, 691-691.	1.4	8
4	First Line BR in Chronic Lymphocytic Leukemia Patients: Interim Results of Russian Norma Trial. <i>Blood</i> , 2014, 124, 3332-3332.	1.4	1
5	Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 5569-5569.	1.4	1
6	Efficacy of Ibrutinib in the Treatment of First Early Relapses of CLL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S216.	0.4	0
7	Impact of MRD Eradication on Survival Outcomes in CLL Patients with Different IGHV Mutation Status. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S273.	0.4	0
8	Efficacy Of Different Therapeutic Approaches In Blastic Phase Of Chronic Myeloid Leukemia: Single Centre Experience. <i>Blood</i> , 2013, 122, 5173-5173.	1.4	0